fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Trospium chloride

2 Limited Use · 1 not a benefit

Mar-Trospium · DIN 02488353 · 20 mg · tablet

Limited Use, Reason for Use code 290 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 290 required
Write on scriptReason for Use code 290 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 290
Reason for Use code 290 For patients with urinary frequency, urgency or urge incontinence who have: Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects. NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed. Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Mar-Trospium · DIN 02488353 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2019-08-30 Health Canada: Marketed since 2019-06-21 · brand MAR-TROSPIUM · ATC G04BD09 TROSPIUM · form Tablet · route Oral · ingredients TROSPIUM CHLORIDE 20 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mar-Trospium: Formulary list price $0.41 per unit (the source does not state the unit; exact figure $0.4072). What the ministry pays, not the patient.

Ministry pays: $0.4072 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02488353)

Source record
DIN 02488353: Mar-Trospium Raw flags: sec12=Y, sec3=Y Item: 920000642; group id 975; item number 2311; lccId 00217; manufacturer id MAR Source form: Tab; strength: 20mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4072; ministry $0.4072 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02488353 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97846
Interchangeable products
Jamp Trospium · DIN 02506661 · $0.4072 Trosec · DIN 02275066 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02488353
Shortage record checked October 6, 2026

Jamp Trospium · DIN 02506661 · 20 mg · tablet

Limited Use, Reason for Use code 290 requiredDormant since August 3, 2026 · checked October 5, 2026 · What does dormant mean?
StatusLimited Use, Reason for Use code 290 required
Write on scriptReason for Use code 290 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 290
Reason for Use code 290 For patients with urinary frequency, urgency or urge incontinence who have: Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects. NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed. Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Jamp Trospium · DIN 02506661 Manufacturer: Jamp Pharma Corporation; listing date 2023-12-29 Health Canada: Dormant since 2026-08-03 · brand JAMP TROSPIUM · ATC G04BD09 TROSPIUM · form Tablet · route Oral · ingredients TROSPIUM CHLORIDE 20 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Trospium: Formulary list price $0.41 per unit (the source does not state the unit; exact figure $0.4072). What the ministry pays, not the patient.

Ministry pays: $0.4072 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02506661)

Source record
DIN 02506661: Jamp Trospium Raw flags: sec12=Y, sec3=Y Item: 920000642; group id 975; item number 2311; lccId 00217; manufacturer id JPC Source form: Tab; strength: 20mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4072; ministry $0.4072 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02506661 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99603
Interchangeable products
Mar-Trospium · DIN 02488353 · $0.4072 Trosec · DIN 02275066 · not recorded
Shortage status: active shortage (reported December 23, 2024, estimated to end January 22, 2027, last updated September 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02506661
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 3, 2026 — choose a marketed DIN from the same-category list.

Trosec · DIN 02275066 · 20 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-08-18 — choose a marketed DIN from the same-category list.Discontinued August 18, 2025 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-08-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-08-18 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 290
Reason for Use code 290 For patients with urinary frequency, urgency or urge incontinence who have: Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects. NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed. Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Trosec · DIN 02275066 Manufacturer: Sunovion Pharmaceuticals Canada Inc.; listing date 2011-12-15 Health Canada: Cancelled post market since 2025-08-18 · brand TROSEC · ATC G04BD09 TROSPIUM · form Tablet · route Oral · ingredients TROSPIUM CHLORIDE 20 MG · company Sunovion pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Trosec: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02275066)

Source record
DIN 02275066: Trosec Raw flags: notABenefit=Y, sec3=Y Item: 920000642; group id 975; item number 2311; lccId 00217; manufacturer id SUO Source form: Tab; strength: 20mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02275066 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76057
Interchangeable products
Jamp Trospium · DIN 02506661 · $0.4072 Mar-Trospium · DIN 02488353 · $0.4072
Shortage status: discontinued (August 18, 2025, reported by SUNOVION PHARMACEUTICALS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02275066
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 18, 2025 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (G04B, G04BD): coverage varies; not interchangeable

  • Darifenacin (Enablex): limited Use 290
  • Solifenacin (Vesicare): limited Use 290
  • Tolterodine l (Detrol LA): limited Use 290
  • Sildenafil (Revatio): not a benefit
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

DARIFENACIN

· 6 products · Limited Use, codes 290 · strengths: 7.5mg, 15mg · ER Tab

SOLIFENACIN SUCCINATE

· 30 products · Limited Use, codes 290 · strengths: 5mg, 10mg · Tab

TOLTERODINE L-TARTRATE

· 12 products · Limited Use, codes 290 · strengths: 2mg, 4mg, 1mg · SR Cap, Tab

SILDENAFIL

· 47 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 25mg, 50mg, 100mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Mar-Trospium (trospium chloride) is indicated for:  the treatment of overactive bladder with symptoms of urge or mixed urinary incontinence, urgency, and urinary frequency. https://pdf.hres.ca/dpd_pm/00051102.PDF PM date: not printed or not captured Source product: MAR-TROSPIUM; DIN 02488353; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Jamp Trospium · DIN 02506661 Shortage status: active shortage (reported 2024-12-23, estimated to end 2027-01-22, last updated 2026-09-28); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02506661

Check this DIN again

Trosec · DIN 02275066 Shortage status: discontinued (2025-08-18, reported by SUNOVION PHARMACEUTICALS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02275066

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Trosec: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026